CRIS - Curis - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

834.5M

Cash

63.49M

Avg Qtr Burn

-11.36M

Short % of Float

1.37%

Insider Ownership

4.87%

Institutional Own.

24.45%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Erivedge (vismodegib) Details BCC (Basal Cell Carcinoma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib)+/- ibrutinib Details Non-Hodgkin lymphoma, Blood cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib) Details Acute myeloid leukemia, Myelodysplastic syndrome, Blood cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib) + Pembrolizumab Details Melanoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CI-8993 (anti-VISTA antibody) Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.